Pharmacotherapy for hypertension in pregnant patients: special considerations

References

• American College of Obstetricians and Gynecologists. Task force on hypertension in pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–1131.
   PubMed Web of Science ®Google Scholar
• Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013;25:124–132.
   PubMed Web of Science ®Google Scholar
• Leffert LR, Clancy CR, Bateman BT, et al. Hypertensive disorders and pregnancy-related stroke: frequency, trends, risk factors, and outcomes. Obstet Gynecol. 2015;125:124–131.
   PubMed Web of Science ®Google Scholar
• Vest AR, Cho LS. Hypertension in pregnancy. Curr Atheroscler Rep. 2014;16:395.
   PubMed Web of Science ®Google Scholar
• Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol. 2012;206:e1–134.e8.
   PubMed Web of Science ®Google Scholar
• Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–e333.
   PubMed Web of Science ®Google Scholar
• Lindheimer MD, Taler SJ, Cunningham FG. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich). 2009;11:214–225.
   PubMed Web of Science ®Google Scholar
• Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ. 2013;347:f6564.
   PubMed Web of Science ®Google Scholar
• Brown MC, Best KE, Pearce MS, et al. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28:1–19.
   PubMed Web of Science ®Google Scholar
• Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:391–403.
   PubMed Web of Science ®Google Scholar
• Ahmad AS, Samuelsen SO. Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies. BJOG. 2012;119:1521–1528.
   PubMed Web of Science ®Google Scholar
• Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation. 2014;129:1254–1261.
   PubMed Web of Science ®Google Scholar
• Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100:369–377.
   PubMed Web of Science ®Google Scholar
• Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 2003;22:203–212.
   PubMed Web of Science ®Google Scholar
• Bellamy L, Casas J-P, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;2018(39):3165–3241.
   Google Scholar
• van Oostwaard MF, Langenveld J, Schuit E, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol. 2015;212:624.e1–624.17.
   PubMed Web of Science ®Google Scholar
• Zeitlin J, El AM, Jarreau PH, et al. Impact of foetal growth restriction on mortality and morbidity in a very preterm birth cohort. J Pediatr. 2010;157:733e9.
   Web of Science ®Google Scholar
• Habli M, Levine RJ, Qian C, et al. Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation. Am J Obstet Gynecol. 2007;197:406.e1–7.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol. 2009;200:481.e1–481.e7.
   Web of Science ®Google Scholar
• Chappell LC, Enye S, Seed P, et al. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008;51:1002–1009.
   PubMed Web of Science ®Google Scholar
• Duley L. The Global Impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–137.
   PubMed Web of Science ®Google Scholar
• Langenveld J, Ravelli ACJ, van Kaam AH, et al. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry. Am J Obstet Gynecol. 2011;205:540.e1–7.
   PubMed Web of Science ®Google Scholar
• Behrens I, Basit S, Melbye M, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078.
   PubMed Web of Science ®Google Scholar
• Harmon QE, Huang L, Umbach DM, et al. Risk of fetal death with preeclampsia. Obstet Gynecol. 2015;125:628–635.
   PubMed Web of Science ®Google Scholar
• Black MH, Zhou H, Sacks DA, et al. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. J Hypertens. 2016;34:728–735.
   PubMed Web of Science ®Google Scholar
• Grandi SM, Filion KB, Yoon S, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. Circulation. 2019;139:1069–1079.
   PubMed Web of Science ®Google Scholar
• Stuart JJ, Tanz LJ, Missmer SA, et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: an observational cohort study. Ann Intern Med. 2018;169:224–232.
   PubMed Web of Science ®Google Scholar
• Wikström A-K, Haglund B, Olovsson M, et al. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112:1486–1491.
   PubMed Web of Science ®Google Scholar
• Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet. 2006;368:1189–1200.
   PubMed Web of Science ®Google Scholar
• Lykke JA, Langhoff-Roos J, Sibai BM, et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944–951.
   PubMed Web of Science ®Google Scholar
• Magnussen EB, Vatten LJ, Smith GD, et al. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol. 2009;114:961–970.
   PubMed Web of Science ®Google Scholar
• Kajantie E, Eriksson JG, Osmond C, et al. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki Birth Cohort Study. Stroke. 2009;40:1176–1180.
   PubMed Web of Science ®Google Scholar
• Theilen LH, Fraser A, Hollingshaus MS, et al. All-cause and cause-specific mortality after hypertensive disease of pregnancy. Obstet Gynecol. 2016;128:238–244.
   PubMed Web of Science ®Google Scholar
• Tooher J, Thornton C, Makris A, et al. Hypertension in pregnancy and long-term cardiovascular mortality: a retrospective cohort study. Am J Obstet Gynecol. 2016;214:722e1–e726.
   Web of Science ®Google Scholar
• Aukes AM, De Groot JC, Aarnoudse JG, et al. Brain lesions several years after eclampsia. Am J Obstet Gynecol. 2009;200:504e1–5.
   Web of Science ®Google Scholar
• Wiegman MJ, de Groot JC, Jansonius NM, et al. Long-term visual functioning after eclampsia. Obstet Gynecol. 2012;119:959–966.
   PubMed Web of Science ®Google Scholar
• Aukes AM, de Groot JC, Wiegman MJ, et al. Long-term cerebral imaging after preeclampsia. BJOG. 2012;119:1117–1122.
   PubMed Web of Science ®Google Scholar
• Robbins CL, Dietz PM, Bombard J, et al. Gestational hypertension: a neglected cardiovascular disease risk marker. Am J Obstet Gynecol. 2011;204:336.e1–9.
   PubMed Web of Science ®Google Scholar
• Romundstad PR, Magnussen EB, Smith GD, et al. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation. 2010;122:579–584.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. (CG107) hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press; 2011.
   Google Scholar
• Magee LA, Pels A, Helewa M, et al. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36:416–441.
   PubMedGoogle Scholar
• Lowe SA, Bowyer L, Lust K, et al. The SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55:e1–29.
   PubMed Web of Science ®Google Scholar
• Brown MA, Magee LA, Kenny LC, et al. International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24–43.
   PubMed Web of Science ®Google Scholar
• Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186:66–71.
   PubMed Web of Science ®Google Scholar
• Gulati M. Early identification of pregnant women at risk for preeclampsia: USPSTF recommendations on screening for preeclampsia. JAMA Cardio. 2017;2:593–595.
   PubMed Web of Science ®Google Scholar
• Bellomo G, Narducci PL, Rondoni F, et al. Prognostic value of 24-hour blood pressure in pregnancy. JAMA. 1999;282:1447–1452.
   PubMed Web of Science ®Google Scholar
• Bar J, Maymon R, Padoa A, et al. White coat hypertension and pregnancy outcome. J Hum Hypertens. 1999;13:541–545.
   PubMed Web of Science ®Google Scholar
• Rodrigues A, Barata C, Marques I, et al. Diagnosis of white coat hypertension and pregnancy outcomes. Pregnancy Hypertens. 2018;14:121–124.
   PubMed Web of Science ®Google Scholar
• Brown MA, Mangos G, Davis G, et al. The natural history of white coat hypertension during pregnancy. BJOG. 2005;112:601–606.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Parati G, Stergiou G, et al. European society of hypertension working group on blood pressure monitoring. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–1768.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378:1509–1520.
   PubMed Web of Science ®Google Scholar
• Gofton EN, Capewell V, Natale R, et al. Obstetrical intervention rates and maternal and neonatal outcomes of women with gestational hypertension. Am J Obstet Gynecol. 2001;185:798–803.
   PubMed Web of Science ®Google Scholar
• Steer PJ, Little MP, Kold-Jensen T, et al. Maternal blood pressure in pregnancy, birth weight, and perinatal mortality in first births: prospective study. BMJ. 2004;329:1312.
   PubMed Web of Science ®Google Scholar
• Davis GK, Mackenzie C, Brown MA, et al. Predicting transformation from gestational hypertension to preeclampsia in clinical practice: a possible role for 24 hour ambulatory blood pressure monitoring. Hypertens Pregnancy. 2007;26:77–87.
   PubMed Web of Science ®Google Scholar
• Anumba DO, Lincoln K, Robson SC. Predictive value of clinical and laboratory indices at first assessment in women referred with suspected gestational hypertension. Hypertens Pregnancy. 2010;29:163–179.
   PubMed Web of Science ®Google Scholar
• Lee-Ann Hawkins T, Brown MA, Mangos GJ, et al. Transient gestational hypertension: not always a benign event. Pregnancy Hypertens. 2012;2:22–27.
   PubMed Web of Science ®Google Scholar
• Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51:970–975.
   PubMed Web of Science ®Google Scholar
• Snydal S. Major changes in diagnosis and management of preeclampsia. J MidwiferyWomens Health. 2014;59:596–605.
   PubMed Web of Science ®Google Scholar
• August P, Malha L. Postpartum hypertension: “it ain’t over ‘til it’s over”. Circulation. 2015;132:1690–1692.
   PubMed Web of Science ®Google Scholar
• Firoz T, Magee LA, MacDonell K, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121:1210–1218.
   PubMed Web of Science ®Google Scholar
• Clark SL, Belfort MA, Dildy GA, et al. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008;199:36.e1–5.
   Web of Science ®Google Scholar
• Martin JN Jr, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105:246–254.
   PubMed Web of Science ®Google Scholar
• Hofmeyr GJ, Lawrie TA, Atallah AN, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014 Jun 24;(6):CD001059. doi: 10.1002/14651858.CD001059.pub4
   Web of Science ®Google Scholar
• Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a metaanalysis. Obstet Gynecol. 2010;116:402–414.
   PubMed Web of Science ®Google Scholar
• WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: World Health Organization; 2011. ISBN-13: 978-92-4-154833-5.
   Google Scholar
• Sibai BM, Koch MA, Freire S, et al. The impact of prior preeclampsia on the risk of superimposed preeclampsia and other adverse pregnancy outcomes in patients with chronic hypertension. Am J Obstet Gynecol. 2011;204:345e1–345.e6.
   Web of Science ®Google Scholar
• Gilbert WM, Young AL, Danielsen B. Pregnancy outcomes in women with chronic hypertension: a population-based study. J Reprod Med. 2007;52:1046–1051.
   PubMed Web of Science ®Google Scholar
• Anderson GD, Carr DB. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin Pharmacokinet. 2009;48:159–168.
   PubMed Web of Science ®Google Scholar
• Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65.
   PubMed Web of Science ®Google Scholar
• Ke AB, Rostami-Hodjegan A, Zhao P, et al. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol. 2014;54:53–69.
   PubMed Web of Science ®Google Scholar
• Pieper PG. Use of medication for cardiovascular disease during pregnancy. Nat Rev Cardiol. 2015;12:718–729.
   PubMed Web of Science ®Google Scholar
• Robson SC, Hunter S, Boys RJ, et al. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 1989;256:H1060–H1065.
   PubMed Web of Science ®Google Scholar
• Capeless EL, Clapp JF. Cardiovascular changes in early phase of pregnancy. Am J Obstet Gynecol. 1989;161:1449–1453.
   PubMed Web of Science ®Google Scholar
• Chapman AB, Abraham WT, Zamudio S, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 1998;54:2056–2063.
   PubMed Web of Science ®Google Scholar
• Mahendru AA, Everett TR, Wilkinson IB, et al. Maternal cardiovascular changes from pre-pregnancy to very early pregnancy. J Hypertens. 2012;30:2168–2172.
   PubMed Web of Science ®Google Scholar
• Macedo ML, Luminoso D, Savvidou MD, et al. Maternal wave reflections and arterial stiffness in normal pregnancy as assessed by applanation tonometry. Hypertension. 2008;51:1047–1051.
   PubMed Web of Science ®Google Scholar
• Fujime M, Tomimatsu T, Okaue Y, et al. Central aortic blood pressure and augmentation index during normal pregnancy. Hypertens Res. 2012;35:633–638.
   PubMed Web of Science ®Google Scholar
• Yoder SR, Thornburg LL, Bisognano JD. Hypertension in pregnancy and women of childbearing age. Am J Med. 2009;122:890–895.
   PubMed Web of Science ®Google Scholar
• Easterling TR, Benedetti TJ, Carlson KC, et al. The effect of maternal hemodynamics on fetal growth in hypertensive pregnancies. Am J Obstet Gynecol. 1991;165:902–906.
   PubMed Web of Science ®Google Scholar
• Easterling TR. Pharmacological management of hypertension in pregnancy. Seminars Perinatol. 2014;38:487–495.
   PubMed Web of Science ®Google Scholar
• Rosano GM, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the working group on pharmacology and drug therapy of the ESC. Eur Heart J. 2015;36:2677–2680.
   PubMedGoogle Scholar
• Haas DM, D’Alton M. Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug? Obstet Gynecol. 2012;120:1176–1179.
   PubMed Web of Science ®Google Scholar
• Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf. 2013;22:1013–1101.
   PubMed Web of Science ®Google Scholar
• Orbach H, Matok I, Gorodischer R, et al. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol. 2013;208:301–306.
   PubMed Web of Science ®Google Scholar
• Fitton CA, Steiner M, Aucott L, et al. In-utero exposure to antihypertensivemedication and neonatal and child health outcomes: a systematic review. J Hypertens. 2017;35:2123–2137.
   PubMed Web of Science ®Google Scholar
• Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003;3:CD002863.
   Google Scholar
• Nakhai-Pour HR, Rey E, Berard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol. 2010;89:147–154.
   PubMedGoogle Scholar
• Davis RL, Eastman D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20:138–145.
   PubMed Web of Science ®Google Scholar
• Molvi SN, Mir S, Rana VS, et al. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet. 2012;285:1553–1562.
   PubMed Web of Science ®Google Scholar
• Yakoob MY, Bateman BT, Ho E, et al. The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension. 2013;62:375–381.
   PubMed Web of Science ®Google Scholar
• Al Khaja KA, Sequeira RP, Alkhaja AK, et al. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014;32:454–463.
   PubMed Web of Science ®Google Scholar
• Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol. 1996;174:823–828.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol. 2008;26:24–30.
   PubMed Web of Science ®Google Scholar
• Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1:647–649
   PubMed Web of Science ®Google Scholar
• el-Qarmalawi AM, Morsy AH, al-Fadly A, et al. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet. 1995;49:125–130.
   PubMed Web of Science ®Google Scholar
• Fidler J, Smith V, Fayers P, et al. Randomized controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. BMJ. 1983;286:1927–1930.
   PubMed Web of Science ®Google Scholar
• Lupattelli A, Spigset O, Nordeng H. Adherence to medication for chronic disorders during pregnancy: results from a multinational study. Int J Clin Pharm. 2014;36:145–153.
   PubMed Web of Science ®Google Scholar
• Caton AR, Bell EM, Druschel CM, et al. National birth defects prevention study. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009;54:63–70.
   PubMed Web of Science ®Google Scholar
• Lennestal R, Otterblad OP, Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. 2009;65:615–625.
   PubMed Web of Science ®Google Scholar
• Caton AR, Bell EM, Druschel CM, et al. National birth defects prevention study. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol. 2008;82:34–40.
   PubMedGoogle Scholar
• Tabacova S, Little R, Tsong Y, et al. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2003;12:633–646.
   PubMed Web of Science ®Google Scholar
• Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443–2451.
   PubMed Web of Science ®Google Scholar
• Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Dev. 2006;82:23–28.
   PubMed Web of Science ®Google Scholar
• Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int. 2012;2012:658310.
   PubMedGoogle Scholar
• Pucci M, Sarween N, Knox E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Rev Clin Pharmacol. 2015;8:221–231.
   PubMed Web of Science ®Google Scholar
• Ruys TP, Maggioni A, Johnson MR, et al. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol. 2014;177:124–128.
   PubMed Web of Science ®Google Scholar
• Hecker A, Hasan SH, Neumann F. Disturbances in sexual differentiation of rat fetuses following spironolactone treatment. Acta Enodcrinol (Copenh). 1980;95:540–545.
   PubMedGoogle Scholar
• Groves TD, Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol. 1995;172:1655–1656.
   PubMed Web of Science ®Google Scholar
• Lydakis C, Lip G, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12:541–547.
   PubMed Web of Science ®Google Scholar
• Reynolds B, Butters L, Evans J, et al. First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child. 1984;59:1061–1063.
   PubMed Web of Science ®Google Scholar
• Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301:587–859.
   PubMed Web of Science ®Google Scholar
• Committee on Obstetric Practice. Emergent therapy for acuteonset, severe hypertension during pregnancy and the postpartum period. Committee Opinion No. 623. American college of obstetricians and gynecologists. Obstet Gynecol. 2015;125:521–525.
   PubMedGoogle Scholar
• Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. BMJ. 1985;290:17–23.
   PubMed Web of Science ®Google Scholar
• Churchill D, Beevers GDG, Meher S, et al. Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev. 2007;(1):CD004451. doi: 10.1002/14651858.CD004451.pub2
   PubMed Web of Science ®Google Scholar
• Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation: reference guide to fetal and neonatal risk. Philadelphia: Lippincott Williams and Wilkins; 2002.
   Google Scholar
• Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol. 2000;96:849–860.
   PubMed Web of Science ®Google Scholar
• Beardmore KS, Morris JM, Gallery ED Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy. 2002;21:85–95.
   PubMed Web of Science ®Google Scholar
• Sibai B, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150:831–835.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–789.
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, et al. Society. Guidelines for management of hypertension: report of the fourth working party of the british hypertension society, – BHS IV. J Hum Hypertens. 2004;18:139–185.
   PubMed Web of Science ®Google Scholar
• Magee L. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf. 2001;24:457–474.
   PubMed Web of Science ®Google Scholar
• von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated meta-regression analysis. J Obstet Gynaecol Can. 2002;24:941–945.
   PubMedGoogle Scholar
• Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2002 Jul 19;2(4). pii: e001185. doi: 10.1136/bmjopen-2012-001185
   Google Scholar
• von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87–92.
   PubMed Web of Science ®Google Scholar
• Magee LA, Elran E, Bull SB, et al. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol. 2000;88:15–26.
   PubMed Web of Science ®Google Scholar
• Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ. 1999;318:1332–1336.
   PubMed Web of Science ®Google Scholar
• Ersbøll AS, Hedegaard M, Søndergaard L, et al. Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG. 2014;121(5):618–626.
   Web of Science ®Google Scholar
• Klarr JM, Bhatt-Mehta V, Donn SM. Neonatal adrenergic blockade following single dose maternal labetalol administration. Am J Perinatol. 1994;11:91–93.
   PubMed Web of Science ®Google Scholar
• Bateman BT, Patorno E, Desai RJ, et al. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics. 2016;138:e20160731.
   PubMed Web of Science ®Google Scholar
• Gelson E, Curry R, Gatzoulis MA, et al. Effect of maternal heart disease on fetal growth. Obstet Gynecol. 2011;117:886–891.
   PubMed Web of Science ®Google Scholar
• Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. Hum Reprod. 2004;19:206–209.
   PubMed Web of Science ®Google Scholar
• Osol G, Mandala M. Maternal uterine vascular remodeling during pregnancy. Physiology (Bethesda). 2009;24:58–71.
   PubMed Web of Science ®Google Scholar
• Kramer MS, Platt R, Yang H, et al. Are all growth-restricted newborns created equal(ly). Pediatrics. 1999;103:599–602.
   PubMed Web of Science ®Google Scholar
• Nakhai-Pour HR, Rey E, Bérard A. Discontinuation of antihypertensive drug use during pregnancy and the risk of pre-eclampsia and eclampsia among women with chronic hypertension. Am J Obstet Gynecol. 2009;180:e1–8.
   Google Scholar
• Cleary KL, Siddiq Z, Ananth CV, et al. Use of antihypertensive medications during delivery hospitalizations complicated by preeclampsia. Obstet Gynecol. 2018;131:441–450.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. ACC/-AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;2018(71):e127–248.
   Google Scholar
• Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;(7):CD001449. doi: 10.1002/14651858.CD001449.pub3
   PubMed Web of Science ®Google Scholar
• Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51:960–969.
   PubMed Web of Science ®Google Scholar
• Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;(10):CD002252. doi: 10.1002/14651858.CD002252.pub4
   Web of Science ®Google Scholar
• von Dadelszen P, Menzies JM, Payne B, et al. Predicting adverse outcomes in women with severe preeclampsia. Semin Perinatol. 2011;33:152–157.
   Web of Science ®Google Scholar
• Nabhan AF, Elsedawy MM. Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension. Cochrane Database Syst Rev. 2011;(7):CD006907. doi: 10.1002/14651858.CD006907.pub2
   PubMed Web of Science ®Google Scholar
• Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:407–417.
   PubMed Web of Science ®Google Scholar
• Magee LA, von Dadelszen P, Singer J, et al. The CHIPS randomized controlled trial (control of hypertension in pregnancy study): is severe hypertension just an elevated blood pressure? Hypertension. 2016;68:1153–1159.
   PubMed Web of Science ®Google Scholar
• Committee on Obstetric Practice. Committee opinion No. 767: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2019;133:e174–e180.
   PubMedGoogle Scholar
• Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118((suppl1)):1–203.
   PubMedGoogle Scholar
• Bernstein PS, Martin JN, Barton JR Jr, et al. Consensus bundle on severe hypertension during pregnancy and the postpartum period. J MidwiferyWomens Health. 2017;62:493–501.
   Web of Science ®Google Scholar
• Cipolla MJ. Cerebrovascular function in pregnancy and eclampsia. Hypertension. 2007;50:14–24.
   PubMed Web of Science ®Google Scholar
• van Veen TR, Panerai RB, Haeri S, et al. Cerebral autoregulation in normal pregnancy and preeclampsia. Obstet Gynecol. 2013;122:1064–1069.
   PubMed Web of Science ®Google Scholar
• Schutte JM, Schuitemaker NEW, van Roosmalen J, et al. Dutch maternal mortality committee. Substandard care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG. 2008;115:732–736.
   PubMedGoogle Scholar
• Scott CA, Bewley S, Rudd A, et al. Incidence, risk factors, management, and outcomes of stroke in pregnancy. Obstet Gynecol. 2012;120:318–324.
   PubMed Web of Science ®Google Scholar
• Foo L, Tay J, Lees CC, et al. Hypertension in pregnancy: natural history and treatment options. Curr Hypertens Rep. 2015;17:36.
   PubMed Web of Science ®Google Scholar
• Practice Bulletin ACOG. Clinical management guidelines for obstetrician-gynecologist, number 202. gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133:e1–e25.
   PubMed Web of Science ®Google Scholar
• Altman D, Carroli G, Duley L, et al. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet. 2002;359:1877–1890.
   PubMed Web of Science ®Google Scholar
• Livingston JC, Livingston LW, Ramsey R, et al. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2003;101:217–220.
   PubMed Web of Science ®Google Scholar
• Vermillion ST, Scardo JA, Newman RB, et al. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol. 1999;181:858–861.
   PubMed Web of Science ®Google Scholar
• Vigil-De Gracia P, Ruiz E, Lopez JC, et al. Management of severe hypertension in the postpartum period with intravenous hydralazine or labetalol: a randomized clinical trial. Hypertens Preg. 2007;26:163–171.
   PubMed Web of Science ®Google Scholar
• Raheem IA, Saaid R, Omar SZ, et al. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012;119:78–85.
   PubMed Web of Science ®Google Scholar
• Moretti MM, Fairlie FM, Akl S, et al. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol. 1990;163:1844–1848.
   PubMed Web of Science ®Google Scholar
• Scardo JA, Vermillion ST, Hogg BB, et al. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol. 1996;175:336–338.
   PubMed Web of Science ®Google Scholar
• Baggio MR, Martins WP, Calderon AC, et al. Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. Ultrasound Med Biol. 2011;37:53–58.
   PubMed Web of Science ®Google Scholar
• Tuffnell DJ, Jankowicz D, Lindow SW, et al. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. Yorkshire obstetric critical care group. BJOG. 2005;112:875–880.
   PubMed Web of Science ®Google Scholar
• Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Cin Pharmacol. 2018;84:1906–1916.
   PubMed Web of Science ®Google Scholar
• Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol. 1993;100:959–961.
   PubMedGoogle Scholar
• Papatsonis DN, Lok CA, Bos JM, et al. Calcium channel blockers in themanagement of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001;97:122–140.
   PubMed Web of Science ®Google Scholar
• Brown MA, Buddle ML, Farrell T, et al. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol. 2002;187:1046–1050.
   PubMed Web of Science ®Google Scholar
• Rezaei Z, Sharbaf FR, Pourmojieb M, et al. Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. Acta Med Iran. 2011;49:701–706.
   PubMedGoogle Scholar
• Martins Costa S, Ramos JG, Barros E, et al. Randomized, controlled trial of hydralazine versos nifedipine in preeclamptic women with acute hypertension. Clin Exp Hypertens B. 1992;11:25–44.
   Google Scholar
• Sørensen HT, Steffensen FH, Olesen C, et al. Pregnancy outcome in women exposed to calcium channel blockers. Reprod Toxicol. 1998;12:383–384.
   PubMed Web of Science ®Google Scholar
• Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol. 1998;105:718–722.
   PubMedGoogle Scholar
• Hubinont C, Debieve F. Prevention of preterm labour: 2011 update on tocolysis. J Pregnancy. 2011;2011:941057.
   PubMedGoogle Scholar
• Waisman GD, Mayorga LM, Camera MI, et al. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol. 1988;159:308–309.
   PubMed Web of Science ®Google Scholar
• Snyder SW, Cardwell MS. Neuromuscular blockade with magnesium sulfate and nifedipine. Am J Obstet Gynecol. 1989;161:35–36.
   PubMed Web of Science ®Google Scholar
• Koontz SL, Friedman SA, Schwartz ML. Symptomatic hypocalcemia after tocolytic therapy with magnesium sulfate and nifedipine. Am J Obstet Gynecol. 2004;190:1773–1776.
   PubMed Web of Science ®Google Scholar
• Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol. 2005;193:153–163.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990;162:960–967.
   PubMed Web of Science ®Google Scholar
• Vigil-De Gracia P, Lasso M, Ruiz E, et al. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;128:157–162.
   PubMed Web of Science ®Google Scholar
• Garden A, Davey DA, Dommisse J. Intravenous labetalol and intravenous dihydralazine in severe hypertension in regnancy. Clin Exp Hypertens B. 1982;1:371–383.
   PubMed Web of Science ®Google Scholar
• Chan WS, Koren G, Barrera M, et al. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy. 2010;29:271–283.
   PubMed Web of Science ®Google Scholar
• Pasker-De Jong PC, Zielhuis GA, van Gelder MM, et al. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG. 2010;117:1080–1086.
   PubMed Web of Science ®Google Scholar
• Sandström B. Antihypertensive treatment with the adrenergic betareceptor blocker metoprolol during pregnancy. Gynecol Invest. 1978;9:195–204.
   PubMedGoogle Scholar
• Mesquita MRDS, Atallah AN, Rocha NDSC, et al. The use of hydralazine and nifedipine in hypertensive emergencies in pregnancy. Rev Bras Ginecol Obstet. 1995;17:103–111.
   Google Scholar
• Moroz LA, Simpson LL, Rochelson B. Management of severe hypertension in pregnancy. Semin Perinatol. 2016;40:112–118.
   PubMed Web of Science ®Google Scholar
• Montan S, Anandakumar C, Arulkumaran S, et al. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1993;168:152–156.
   PubMed Web of Science ®Google Scholar
• Magee LA, CHIPS Study Group, von Dadelszen P, et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the control of hypertension in pregnancy study (CHIPS) trial. BJOG. 2016;123:1143–1151.
   PubMed Web of Science ®Google Scholar
• Sass N, Itamoto CH, Silva MP, et al. Does sodium nitroprusside kill babies? A systematic review. Sao Paulo Med J. 2007;125:108–111.
   PubMed Web of Science ®Google Scholar
• Neri I, Valensise H, Facchinetti F, et al. 24-hour ambulatory blood pressure monitoring: a comparison between transdermal glyceryl-trinitrate and oral nifedipine. Hypertens Pregnancy. 1999;18:107–113.
   PubMed Web of Science ®Google Scholar
• Cetin A, Yurtcu N, Guvenal T, et al. The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia, HELLP syndrome, and eclampsia. Hypertens Pregnancy. 2004;23:37–46.
   PubMed Web of Science ®Google Scholar
• Hernandez-Sierra JF, Rodriguez-Martinez M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe preeclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol. 2008;35:580–585.
   PubMed Web of Science ®Google Scholar
• Samadi AR, Mayberry RM, Zaidi AA, et al. Maternal hypertension and associated pregnancy complications among African-American and other women in the United States. Obstet Gynecol. 1996;87:557–563.
   PubMed Web of Science ®Google Scholar
• Healy AJ, Malone FD, Sullivan LM, et al. Early access to prenatal care: implications for racial disparity in perinatal mortality. Obstet Gynecol. 2006;107:625–631.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Einhorn PT, Muntner P, et al. Research needs to improve hypertension treatment and control in African Americans. Hypertension. 2016;68:1066–1072.
   PubMed Web of Science ®Google Scholar
• Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One. 2016;11:e0147601.
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22.
   PubMed Web of Science ®Google Scholar
• Bramham K, Nelson-Piercy C, Brown MJ, et al. Postpartum management of hypertension. BMJ. 2013;346:f894.
   PubMedGoogle Scholar
• Goel A, Maski MR, Bajracharya S, et al. Epidemiology and mechanisms of De Novo and persistent hypertension in the postpartum period. Circulation. 2015;132:1726–1733.
   PubMed Web of Science ®Google Scholar
• Cairns AE, Pealing L, Duffy JMN, et al. Postpartum management of hypertensive disorders of pregnancy: a systematic review. BMJ Open. 2017;7:e018696.
   PubMed Web of Science ®Google Scholar
• Magee L, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351. doi: 10.1002/14651858.CD004351.pub3
   PubMed Web of Science ®Google Scholar
• Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol. 2004;190:577–578.
   PubMed Web of Science ®Google Scholar
• Snowden S, Nelson R. The effects of nonsteroidal antiinflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011;19:184–191.
   PubMed Web of Science ®Google Scholar
• Wasden SW, Ragsdale ES, Chasen ST, et al. Impact of non-steroidal anti-inflammatory drugs on hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4:259–263.
   PubMed Web of Science ®Google Scholar
• Viteri OA, England JA, Alrais MA, et al. Association of nonsteroidal antiinflammatory drugs and postpartum hypertension in women with preeclampsia with severe features. Obstet Gynecol. 2017;130:830–835.
   PubMed Web of Science ®Google Scholar
• Blue NR, Murray-Krezan C, Drake-Lavelle S, et al. Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial. Am J Obstet Gynecol. 2018;218:616.e1–8.
   PubMed Web of Science ®Google Scholar